Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

MK 0852

Known as: MK 852, MK-852, MK-0852 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2003
2003
SUMMARY The effects of the GPIIb-IIIa antagonists abciximab and MK-852 on platelet-leukocyte interactions in vitro were studied… Expand
2003
2003
This study was to investigate the appearance of P-selectin, tissue factor (TF) and CD40 ligand (CD40L) on platelet-leucocyte… Expand
2000
2000
MK‐852, a cyclic heptapeptide, is a potent platelet fibrinogen receptor antagonist When administered to normal healthy male… Expand
Highly Cited
1998
Highly Cited
1998
Platelet activation is accompanied by changes in the composition of the platelet cytoskeleton with rapid incorporation and… Expand
1998
1998
A critical function of fibrinogen in hemostasis and thrombosis is to mediate platelet aggregation by binding selectively to an… Expand
  • figure 2
  • figure 1
  • figure 3
  • figure 4
  • figure 5
1998
1998
Platelets in stirred whole blood can be induced to form aggregates and also to form heterotypic platelet-monocyte (P/M) and… Expand
Highly Cited
1998
Highly Cited
1998
BACKGROUND Citrated platelet-rich plasma (PRP) turbidimetry is used for assessing pharmacodynamic effects of glycoprotein (GP… Expand
  • figure 1
  • figure 2
  • table 2
  • table 1
1996
1996
Platelet activation by adenosine diphosphate (ADP) results in an alteration in the composition of the cytoskeleton. Here we have… Expand
Highly Cited
1995
Highly Cited
1995
BACKGROUND Thrombin inhibitors have been shown to be efficacious in animal models of thrombosis and in initial human clinical… Expand
1993
1993
The antiaggregatory and antithrombotic actions of MK-0852, a cyclic heptapeptide antagonist of the platelet GP IIb/IIIa, were… Expand